2021-07-29| Asia-Pacific

Japan’s Chugai Infuses $500 Million for a New API Manufacturing Building

by Tyler Chen
Share To

With nearly $500 million (55.5 billion yen) investment, Japan’s Chugai Pharmaceutical adds another manufacturing building to produce active pharmaceutical ingredients (APIs) for small and mid-size molecule drugs. This is the third building Chugai established for this drug type.


FJ3 to Support Clinical Trials to Market Launch

The building, also known as FJ3, will be located in the Fujieda Plant along with FJ1 and FJ2 and is expected to go into full operation in March 2025.

“FJ3 will be a world-class production facility with advanced production technologies and automate manufacturing operations which enable labor-saving and productivity improvements, as well as thoroughly considering environment and safety,” said Osamu Okuda, President, and CEO of Chugai.

FJ3 will be a five-story isolated building and installed API production lines with advanced containment technologies to meet the manufacturing needs as more candidates are about to enter clinical trials. The facility will produce high potency API from early clinical trials to market launches.

The construction of FJ3 will begin in 2022 and finish in February 2024. Currently, FJ2 is still under construction and will be completed in 2022.

The mid-size molecule is Chugai’s third modality, following small molecules and antibodies. With the expectation of mid-size molecule drugs being the driving force for the firm’s medium to long-term growth, Chugai has established two buildings for production in 2019 and 2021.

Related Article: Chugai Initiates Actemra’s Phase 3 COVID-19 Trials in Japan

© All rights reserved. Collaborate with us:
Related Post
Neurolief’s Neuromodulation Device Receives Japanese Approval for At-Home Migraine Treatment
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
Ajinomoto to Acquire Forge Biologics for $620 Million to Boost Gene Therapy Capabilities
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
Pharmacogenomics (PGx) Shaping the Dynamic APAC Regions
Connecting Biotech Ecosystems: Success of Los Angeles Event Sets Stage for APAC-US Collaboration
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
Scroll to Top